Sign In

Friday, March 16, 2018 - 8:00 am to Saturday, March 17, 2018 - 12:45 pm
Add to Calendar

Course Description/Need Statement

The Emerging Trends Conference - Cholangiopathies: The Dawn of Curative Treatments? conference will review the most recent advances in genetics, pathogenesis and treatment opportunities of cholangiopathies. The conference will assist in facilitating the development of new research collaborations and clinical trials to improve the outcome of children and adults with biliary diseases. Future research directions, including biomarker development and emerging therapeutic possibilities will also be discussed in depth.

Program Chairs

  • Mario Strazzabosco, MD, PhD, FAASLD
  • Christopher L. Bowlus, MD, FAASLD

Location

  • Crystal Gateway Marriott
    Arlington, VA

Course Syllabus

  • The course syllabus will be available in March 2018.

Continuing Education

  • CME – 11.0 AMA PRA Category 1 Credits™
  • ABIM MOC - 11.0 Points

Registration Pricing Early Bird: On or Before February 14

  • Member $325
  • Trainee & Assoc. Members $185
  • Student Member $90
  • Non-Member $540
    Any physician, scientist, or researcher with doctoral-level training who is not employed by Industry (pharma/device/etc.)
  • Trainee & Assoc. Non-Member $235
    Any physician, scientist or researcher in a training program as certified by the director of their training program. This category also includes, but is not limited to, the degrees of MS, NP, PA, RN, and other related or comparable degrees.
  • Student Non-Member $115
  • Industry $775
    Any Industry (pharma/device/etc.) employee with or without medical training.

* Requests for cancellations must be submitted in writing to meetings@aasld.org. Cancellations received: on or before February 14 will be refunded in full. Refunds between February 15 and February 28 will be subject to a $50.00 cancellation fee. Cancellations on or after March 1 are not eligible for a refund.

Registration Pricing Early Bird: On or After February 15

  • Member $425
  • Trainee & Assoc. Members $210
  • Student Member $105
  • Non-Member $640
    Any physician, scientist, or researcher with doctoral-level training who is not employed by Industry (pharma/device/etc.)
  • Trainee & Assoc. Non-Member $260
    Any physician, scientist or researcher in a training program as certified by the director of their training program. This category also includes, but is not limited to, the degrees of MS, NP, PA, RN, and other related or comparable degrees.
  • Student Non-Member $130
  • Industry $875
    Any Industry (pharma/device/etc.) employee with or without medical training.

* Requests for cancellations must be submitted in writing to meetings@aasld.org. Cancellations received on or before February 14 will be refunded in full. Refunds between February 15 and February 28 will be subject to a $50.00 cancellation fee. Cancellations on or after March 1 are not eligible for a refund.

Session I: Targeting Bile Acids and Bile Secretion

Friday, March 16

Moderators: Cynthia Levy, MD, FAASLD and Michael H. Trauner, MD, FAASLD

  • 7am
    Breakfast
  • 8–8:15 am
    Welcome and Course Objectives
    Christopher L. Bowlus, MD, FAASLD 
  • 8:15–8:45 am
    Unmet Needs in Cholangiopathies
    Mario Strazzabosco, MD, PhD, FAASLD 
  • 8:45–9:05 am
    Bile Acids in Health and Disease and their Potential Targets for Therapies
    Michael H. Trauner, MD, FAASLD 
  • 9:05–9:25 am
    Bile Acids Clinical Treatments 
    Elizabeth J. Carey, MD, FAASLD
  • 9:25–9:55 am
    Panel Discussion 
  • 9:55–10:15 am
    Break

Session II: Targeting Inflammation

Friday, March 16

Moderators: David H. Adams, MD and Jorge A. Bezerra, MD, FAASLD

  • 10:15–10:35 am
    Immune Response and Inflammation in Cholangiopathies and Cholestatic Liver Diseases
    David H. Adams, MD
  • 10:35–10:55 am
    Autoinflammation in Congenital Hepatic Fibrosis
    Carlo Spirli, PhD
  • 10:55–11:15 am 
    Immuno-modulatory Strategies for Cholangiopathies
    John M. Vierling, MD, FAASLD
  • 11:15–11:45 am
    Panel Discussion
  • 11:45 am–1:15 pm
    Lunch and Poster Session

Session III: Targeting Biliary Fibrosis

Friday, March 16

Moderators: Natalie J. Torok, MD, MSc, FAASLD and Rebecca G. Wells, MD

  • 1:15–1:35 pm
    Cross-Talk Epithelial-Mesenchymal Cells in Biliary Fibrosis
    Rebecca G. Wells, MD
  • 1:35–1:55 pm
    Targeting Fibrosis in Cholangiopathies
    Natalie J. Torok, MD, MSc, FAASLD
  • 1:55–2:15 pm
    Targeting Biliary Fibrosis and Inflammation in Biliary Atresia
    Jorge A. Bezerra, MD, FAASLD
  • 2:15–2:35 pm
    Targeting Morphogens 
    Satdarshan (Paul) Singh Monga, MD, FAASLD
  • 2:35–2:55 pm
    Panel Discussion
  • 2:55–3:15 pm
    Break

Session IV: Nuclear Receptors and Cholangiopathies

Friday, March 16

Moderators: Saul J. Karpen, MD, PhD, FAASLD and Olivier Barbier, PhD

  • 3:15–3:35 pm
    Nuclear Receptors and Cholangiopathies
    Saul J. Karpen, MD, PhD, FAASLD 
  • 3:35–3:55 pm
    Fibrates, PPARs and Bile Acids Metabolism
    Olivier Barbier, PhD 
  • 3:55–4:15 pm
    Clinical Experience with Fibrates and Other PPARs Agonists
    Cynthia Levy, MD, FAASLD 
  • 4:15–4:35 pm
    Panel Discussion

Session V: Abstract Presentations

Saturday, March 17

Moderators: Carlo Spirli, PhD

  • 7am
    Breakfast
  • 8– 8:10 am
    Announcement of Poster Awards
  • 8:10–8:25 am
    Oral Presentation #1
  • 8:25–8:40 am
    Oral Presentation#2

Session VI: Genetic Cholangiopathies and Personalized Medicine

Saturday, March 17

Moderators: Keith D. Lindor, MD, FAASLD and Mario Strazzabosco, MD, PhD, FAASLD

  • 8:40–9 am
    Translational Advances in Cystic Fibrosis Cholangiopathy
    Romina Fiorotto, PhD 
  • 9– 9:20 am 
    Translational Advances in Polycystic Liver Diseases
    Nicholas F. LaRusso, MD, FAASLD 
  • 9:20– 9:40 am
    Special Populations and Cholangiopathies
    Marina G. Silveira, MD
  • 9:40–10 am
    Panel Discussion
  • 10–10:20 am
    Break

 

Session VII: Moving Therapeutics to the Clinic

Saturday, March 17

Moderators: Christopher L. Bowlus, MD, FAASLD and Cyriel Ponsioen, MD, PhD

  • 10:20–10:40 am
    Development of Surrogate Markers and Post-Approval Validation in PBC
    Marco Carbone, MD
  • 10:40–11 am
    Bio-Markers of Disease Progression in PSC
    Cyriel Ponsioen, MD PhD
  • 11–11:20 am
    Patient Reported Outcomes in PSC and PBC
    Donna M. Evon, PhD
  • 11:20–11:40 am
    Pathways for Regulatory Approval of New Therapies for Cholestatic Liver Diseases
    Suna Seo, MD
  • 11:40 am–Noon
    Clinical Trial Design for PBC in the Era of UDCA and OCA
    Keith D. Lindor, MD, FAASLD
  • Noon–12:20 pm
    The Patient Perspective
    Ricky Safer
  • 12:20–12.40 pm
    Panel Discussion
  • 12:40–1:00 pm
    Conference Summary and Wrap-Up
    Mario Strazzabosco, MD, PhD, FAASLD
  • 1:00 pm
    Adjourn